Opiant Pharmaceuticals (OPNT) 10-Q 14 Jun 17 2017 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Apr. 30, 2017	Jun. 06, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Apr. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Entity Registrant Name	OPIANT PHARMACEUTICALS, INC.
Entity Central Index Key	1,385,508
Current Fiscal Year End Date	--07-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	OPNT
Entity Common Stock, Shares Outstanding		2,026,608

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Apr. 30, 2017	Jul. 31, 2016
Current assets
Cash and cash equivalents	$ 9,680,454	$ 1,481,393
Accounts receivable	0	312,498
Prepaid expenses	98,911	62,404
Total current assets	9,779,365	1,856,295
Other assets
Computer equipment (net of accumulated amortization of $3,842 at April 30, 2017 and $1,016 at July 31, 2016)	3,695	6,521
Patents and patent applications (net of accumulated amortization of $9,417 at April 30, 2017 and $8,388 at July 31, 2016)	18,033	19,062
Total assets	9,801,093	1,881,878
Current liabilities
Accounts payable and accrued liabilities	1,390,780	140,584
Accrued salaries and wages	1,543,142	3,681,250
Note payable	0	165,000
Deferred revenue	194,800	250,000
Total current liabilities	3,128,722	4,236,834
Deferred revenue	2,387,084	2,350,000
Total liabilities	5,515,806	6,586,834
Stockholders' equity (deficit)
Common stock; par value $0.001; 1,000,000,000 shares authorized; 2,020,380 shares issued and outstanding at April 30, 2017 and 1,992,433 shares issued and outstanding at July 31, 2016	2,020	1,992
Additional paid-in capital	58,549,055	56,478,394
Accumulated deficit	(54,265,788)	(61,185,342)
Total stockholders' equity (deficit)	4,285,287	(4,704,956)
Total liabilities and stockholders' equity (deficit)	$ 9,801,093	$ 1,881,878

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Apr. 30, 2017	Jul. 31, 2016
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 3,842	$ 1,016
Finite-Lived Intangible Assets, Accumulated Amortization (in dollars)	$ 9,417	$ 8,388
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common Stock, Shares, Issued	2,020,380	1,992,433
Common Stock, Shares, Outstanding	2,020,380	1,992,433

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Revenue
Royalty and licensing revenue	$ 0	$ 2,605,097	$ 14,656,142	$ 4,785,097
Treatment investment revenue	18,116	0	18,116	4,800,000
Total revenue	18,116	2,605,097	14,674,258	9,585,097
Operating expenses
General and administrative	1,995,892	1,040,608	4,567,898	13,155,931
Research and development	1,103,319	1,059,627	1,889,989	2,814,520
Selling expenses	84,375	93,000	1,322,974	302,251
Total operating expenses	3,183,586	2,193,235	7,780,861	16,272,702
Income (loss) from operations	(3,165,470)	411,862	6,893,397	(6,687,605)
Other income (expense)
Interest income (expense), net	10,673	0	9,306	(11,319)
Income (loss) on foreign exchange	25,189	4,266	16,851	(24,925)
Total other income (expense)	35,862	4,266	26,157	(36,244)
Income (loss) before provision for income taxes	(3,129,608)	416,128	6,919,554	(6,723,849)
Provision for income taxes	0	0	0	0
Net income (loss)	$ (3,129,608)	$ 416,128	$ 6,919,554	$ (6,723,849)
Basic income (loss) per common share	$ (1.55)	$ 0.22	$ 3.45	$ (3.57)
Diluted income (loss) per common share	$ (1.55)	$ 0.15	$ 3.07	$ (3.57)
Basic weighted average common shares outstanding	2,014,141	1,916,554	2,004,143	1,882,088
Diluted weighted average common shares outstanding	2,014,141	2,734,760	2,251,127	1,882,088

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Deficit) - 9 months ended Apr. 30, 2017 - USD ($)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Balance at Jul. 31, 2016	$ (4,704,956)	$ 1,992	$ 56,478,394	$ (61,185,342)
Balance, shares at Jul. 31, 2016		1,992,433
Stock issued for services	190,427	$ 28	190,399	0
Stock issued for services (in shares)		27,947
Stock based compensation from issuance of stock options	889,076	$ 0	889,076	0
Stock based compensation from issuance of stock warrants	229,360	0	229,360	0
Forgiveness of related party debt	761,826	0	761,826	0
Net income	6,919,554	0	0	6,919,554
Balance at Apr. 30, 2017	$ 4,285,287	$ 2,020	$ 58,549,055	$ (54,265,788)
Balance, shares at Apr. 30, 2017		2,020,380

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016
Cash flows used in operating activities
Net income (loss)	$ 6,919,554	$ (6,723,849)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Amortization	3,855	1,187
Issuance of common stock for services	190,427	1,215,719
Stock based compensation from issuance of options	889,076	10,183,555
Stock based compensation from issuance of warrants	229,360	0
Changes in assets and liabilities:
Increase in prepaid expenses	(36,507)	(37,233)
Decrease in accounts receivable	312,498	0
Decrease in deferred revenue	(18,116)	(4,300,000)
Increase (decrease) in accounts payable	1,250,196	(108,639)
Increase (decrease) in accrued salaries and wages	(1,376,282)	501,536
Net cash provided by operating activities	8,364,061	732,276
Cash flows used in investing activities
Purchase of equipment	0	(6,528)
Net cash used in investing activities	0	(6,528)
Cash flows provided by financing activities
Proceeds from related parties notes payable	0	151,191
Repayment of related parties notes payable	0	(281,191)
Repayment of note payable	(165,000)	0
Investment received in exchange for royalty agreement	0	1,333,500
Net cash provided (used) by financing activities	(165,000)	1,203,500
Net increase in cash and cash equivalents	8,199,061	1,929,248
Cash and cash equivalents, beginning of period	1,481,393	434,217
Cash and cash equivalents, end of period	9,680,454	2,363,465
Supplemental disclosure
Interest paid during the period	4,828	78,865
Taxes paid during the period	0	0
Non-Cash Transactions
Forgiveness of related party debt	761,826	0
Cashless exercise of options	$ 0	$ 15

Organization and Basis of Prese

Organization and Basis of Presentation	9 Months Ended
	Apr. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	1. Organization and Basis of Presentation Opiant Pharmaceuticals, Inc. (the “Company”), a Nevada corporation, is a specialty pharmaceutical company which develops pharmacological treatments for substance use, addictive, and eating disorders. The Company was incorporated in the State of Nevada on June 21, 2005 as Madrona Ventures, Inc. and on September 16, 2009, the Company changed its name to Lightlake Therapeutics Inc. On January 28, 2016, the Company again changed its name to Opiant Pharmaceuticals, Inc. The Company is developing opioid antagonist treatments for substance use, addictive, and eating disorders. The Company also has developed a treatment to reverse opioid overdoses, which is now known as NARCAN® (naloxone hydrochloride) Nasal Spray. The Company’s fiscal year end is July 31. The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S.”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, these consolidated financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and such adjustments are of a normal recurring nature. These consolidated financial statements should be read in conjunction with the financial statements for the year ended July 31, 2016 and notes thereto and other pertinent information contained in the Form 10-K the Company has filed with the Securities and Exchange Commission (the “SEC”). The results of operations for the three months and nine months ended April 30, 2017 are not necessarily indicative of the results for the full fiscal year ending July 31, 2017.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Apr. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the U.S. (“GAAP”), which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Opiant Pharmaceuticals UK Limited, a company incorporated on November 4, 2016 under the England and Wales Companies Act of 2006. Intercompany balances and transactions are eliminated upon consolidation. Earnings (loss) per share is calculated by dividing the net income (loss) available to common stockholders by the weighted average number of shares outstanding during the period. Diluted earnings per share reflect the potential dilution of securities that could share in earnings of an entity. Diluted income per share reflects the potential dilution that would occur if outstanding stock options and warrants were exercised utilizing the treasury stock method. In a loss year, dilutive common equivalent shares are excluded from the loss per share calculation as the effect would be anti-dilutive. For the Three Months Ended April 30, 2017 2016 Weighted Weighted Average Average Common Common Loss Shares Per Share Income Shares Per Share $ Outstanding $ $ Outstanding $ Basic: Income (loss) attributable to common stock (3,129,608) 2,014,141 (1.55) 416,128 1,916,554 0.22 Effective of Dilutive Securities: Stock options and warrants – – – – 818,206 – Diluted: Income (loss) attributable to common stock, including assumed conversions (3,129,608) 2,014,141 (1.55) 416,128 2,734,760 0.15 For the Nine Months Ended April 30, 2017 2016 Weighted Weighted Average Average Common Common Income Shares Per Share Loss Shares Per Share $ Outstanding $ $ Outstanding $ Basic: Income (loss) attributable to common stock 6,919,554 2,004,143 3.45 (6,723,849) 1,882,088 (3.57) Effective of Dilutive Securities: Stock options and warrants – 246,984 – – – – Diluted: Income (loss) attributable to common stock, including assumed conversions 6,919,554 2,251,127 3.07 (6,723,849) 1,882,088 (3.57) Certain amounts in the April 30, 2016 financial statements have been reclassified to conform to the presentation in the April 30, 2017 consolidated financial statements. The Company has implemented all new accounting pronouncements that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Apr. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	3. Related Party Transactions The Company uses office space provided by Dr. Michael Sinclair and Kevin Pollack free of charge. On March 31, 2017, Dr. Michael Sinclair, the Executive Chairman of the Board of Directors of the Company (the “Board”), and Dr. Roger Crystal, the Company’s Chief Executive Officer, each voluntarily entered into separate employment agreement acknowledgements whereby they elected to forfeit, unconditionally and irrevocably, $ 175,498 586,328 35 Furthermore, on March 31, 2017, pursuant to their respective employment agreement acknowledgements, Dr. Sinclair and Dr. Crystal each voluntarily elected to forfeit, unconditionally and irrevocably, 680,000 825,000 0.001 55

Note Payable

Note Payable	9 Months Ended
	Apr. 30, 2017
Debt Disclosure [Abstract]
Note Payable	4. Note Payable On June 21, 2016, the Company entered into a settlement and release agreement with a former advisor pursuant to which, in exchange for prior advisory services rendered to the Company in full pursuant to an advisory services agreement dated on or about September 17, 2012, the Company has agreed to pay the $ 165,000 6 2,200,000 22,916 165,000

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Apr. 30, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity	5. Stockholders’ Equity Common Stock On November 2, 2016, the Company granted 1,000 7.52 7,520 7,520 On November 10, 2016, the Company issued 14,327 5.94 85,102 85,102 On March 16, 2017, the Company issued 10,745 7.75 83,274 83,274 On March 16, 2017, the Company issued 1,875 7.75 14,531 14,531 Stock Options As required by the Stock Compensation Topic, ASC 718, the Company measures and recognizes compensation expense for all share based payment awards made to the officers and directors based on estimated fair values at the grant date and over the requisite service period. On October 6, 2016, the Company granted options to purchase a total of 50,000 10.00 10 1,388 1,390 425,000 213,282 On November 4, 2016, the Company appointed Thomas T. Thomas to the Board and granted Mr. Thomas an option to purchase 35,000 10.00 5 vests as follows: (i) 11,667 shares vest upon the uplisting of the Company to the NASDAQ Stock Market; (ii) 11,667 shares vest upon the cumulative funding of the Company of or in excess of $5,000,000 by institutional investors starting from November 4, 2016; and 11,666 shares vest upon the first submission of a New Drug Application to the U.S. Food and Drug Administration for one of Company’s products by Company itself or a Company licensee. 220,116 134,188 On December 24, 2016, the Company granted an option to purchase a total of 35,000 10.00 10 972 973 219,450 75,363 On February 6, 2017, the Company granted an option to purchase 200,000 10 9.00 100,000 5,555 5,556 1,600,000 223,925 1,376,075 The Company also recognized stock based compensation expense of $ 242,318 On March 31, 2017, pursuant to their respective employment agreement acknowledgements, Dr. Sinclair and Dr. Crystal each voluntarily elected to forfeit, unconditionally and irrevocably, 395,000 785,000 2017 2016 Market value of stock on measurement date $5.61 to 8.71 $ 7.00 Risk-free interest rate 0.88-2.55 % 2.05 % Dividend yield 0 % 0 % Volatility factor 97-348 % 373 % Term 2.53-10.00 years 10 years Weighted- Weighted- Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Term (Years) Value Outstanding at July 31, 2016 4,635,000 $ 8.79 7.39 $ 2,731,250 Granted 320,000 $ 9.38 Expired (2,500) $ 10.00 Forfeited (1,180,000) $ 11.03 Outstanding at April 30, 2017 3,772,500 $ 8.13 7.12 $ 975,000 Exercisable at April 30, 2017 3,303,882 $ 7.75 7.21 $ 975,000 A summary of the status of the Company’s non-vested options as of April 30, 2017 and changes during the nine months ended April 30, 2017 are presented below: Non-vested options Weighted Average Number of Grant Date Fair Options Value Non-vested at July 31, 2016 90,833 $ 7.27 Granted 320,000 $ 7.70 Vested (59,717) $ 6.93 Non-vested at April 30, 2017 351,116 $ 7.73 At April 30, 2017, there was $ 2,001,413 Warrants On March 13, 2017, the Company granted a warrant to purchase 45,000 10.00 8.00 10.00 111 1.63 229,360 On March 31, 2017, Dr. Michael Sinclair, the Executive Chairman of the Board, and Dr. Roger Crystal, the Company’s Chief Executive Officer, each voluntarily entered into separate employment agreement acknowledgements whereby they elected to forfeit, unconditionally and irrevocably, 285,000 40,000 Weighted- Weighted- Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Term (Years) Value Outstanding at July 31, 2016 1,215,385 $ 17.90 2.86 $ - Granted 45,000 $ 10.00 Expired (162,300) $ 47.23 Forfeited (325,000) $ 15.00 Outstanding at April 30, 2017 773,085 $ 12.51 3.27 $ - Exercisable at April 30, 2017 373,085 $ 9.84 6.06 $ -

Commitments

Commitments	9 Months Ended
	Apr. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments	6. Commitments a) On December 18, 2014, the Company entered into a consulting agreement. Pursuant to the agreement, the consultant agreed to provide financial advisory services with regard to a licensing agreement. In exchange for these services, the Company incurred fixed fees of $ 225,000 75,000 3.75 3,000,000 635,474 209,251 b) On April 25, 2016, the Company entered into a consulting agreement. Pursuant to the agreement, the consultant agreed to provide financial advisory services. In exchange for these services, the Company is required to pay a fee on all funding received by the Company as a result of assistance provided by the consultant. Pursuant to the agreement, the consultant’s fee will be equal to 5% of gross funding received by the Company up to $20,000,000 plus 3.5% of any proceeds received in excess of $20,000,000 687,500 c) On November 19, 2015, the Company issued 14,327 120,347 92,634 3,582 14,327 85,102 10,745 7.75 83,274 83,274 d) In October 2016, the Company in-licensed a heroin vaccine from Walter Reed Army Institute of Research. In consideration for the license the Company agreed to pay a royalty of 3 4 10,000 715,672 e) The Company leases office space in four locations. The Company’s headquarters are located on the 12th Floor of 401 Wilshire Blvd., Santa Monica, CA 90401, which the Company leases from Premier Office Centers, LLC (“Premier”). Per the terms of the amended lease dated October 1, 2016, the initial lease term is for five months with a monthly rent of $ 5,056 5,157 The Company also leases office space in Suite 100 of 1180 North Town Center Drive, Las Vegas, NV 89144 for $ 299 July 31, 2017 Additionally, the Company leases office space in Euston Tower, L32 to L34, 286 Euston Road, London, England, NW1 3DP for a total of € 1,932 On April 20, 2017, the Company entered into an Office Service Agreement (the “Office Service Agreement”) with Regus to lease office space at 83 Baker Street, London, England, W1U 6AG. Per the terms of the Office Service Agreement, the first month’s rent is £ 2,473 7,521 15,042 May 31, 2018 f) On February 3, 2017, the Company entered into the Skolnick Employment Agreement whereby Dr. Skolnick became the Company’s Chief Scientific Officer effective February 6, 2017. The Skolnick Employment Agreement has an initial term of six (6) months. Following the initial term, the Skolnick Employment Agreement, unless otherwise terminated, shall extend on a month-to-month basis. Under the Skolnick Employment Agreement, Dr. Skolnick (i) received a one-time cash sign-on bonus of $ 40,000 410,000 200,000 In addition, the Skolnick Employment Agreement provides for benefits if Dr. Skolnick’s employment is terminated under certain circumstances. In the event the Company terminates Dr. Skolnick’s employment for Cause (as defined in the Skolnick Employment Agreement), Dr. Skolnick will receive accrued but unpaid base salary and vacation through the date of termination of his employment (the “Termination Date”). In the event the Company terminates Dr. Skolnick’s employment or if Dr. Skolnick resigns within twelve months of a Constructive Termination (as defined in the Skolnick Employment Agreement) of Dr. Skolnick’s employment, and in either case such termination is not for Cause, then the Company shall pay Dr. Skolnick the sum of: (i) accrued but unpaid base salary and vacation through the Termination Date; (ii) one times his annual salary; and (iii) one times his bonus cash compensation, excluding the signing bonus, awarded to Dr. Skolnick in 2017. In the event of such termination, all outstanding stock options, warrants, restricted share awards, performance grants held by Dr. Skolnick shall become fully vested and remain exercisable for the life of such award and shall not be forfeited for any reason whatsoever. In the event of a Fundamental Transaction, Dr. Skolnick shall be entitled to receive the sum of: (i) accrued but unpaid base salary and vacation through the Termination Date; (ii) one times his annual salary; and (iii) one times his bonus cash compensation, excluding the signing bonus, awarded to Dr. Skolnick in 2017. In the event of a Fundamental Transaction, all outstanding stock options, warrants, restricted share awards, performance grants held by Dr. Skolnick shall become fully vested and remain exercisable for the life of such award and shall not be forfeited for any reason whatsoever. g) On March 13, 2017, the Company entered into a third amendment (the “Third Miles Amendment”) to that certain Senior Advisor Agreement with Brad Miles, dated January 22, 2013 (the “Initial Miles Agreement”), as previously amended on February 24, 2015 (the “First Miles Amendment”) and March 19, 2015 (the “Second Miles Amendment” and, together with the Initial Miles Agreement, the First Miles Amendment and the Third Miles Amendment, the “Miles Agreement”). Pursuant to the Third Miles Amendment, and in consideration for Mr. Miles’ continued service to the Company as an advisor through December 31, 2017, the Company: (i) paid Mr. Miles $ 107,805 1,875 1.25 1.25 17,000 45,000 10.00 187,500 1.25

Sale of Royalties

Sale of Royalties	9 Months Ended
	Apr. 30, 2017
Sale of Royalties [Abstract]
Sale of Royalties	7. Sale of Royalties On December 13, 2016, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with SWK Funding LLC (“SWK”) pursuant to which the Company sold, and SWK purchased, the Company’s right to receive, commencing on October 1, 2016, all Royalties arising from the sale by Adapt, pursuant to that certain License Agreement between the Company and Adapt, dated as of December 15, 2014, as amended (the “Adapt Agreement”), of NARCAN® (naloxone hydrochloride) Nasal Spray (“NARCAN®”) or any other Product, up to (i) $20,625,000 and then the Residual Royalty thereafter or (ii) $26,250,000, if Adapt has received in excess of $25,000,000 of cumulative Net Sales for any two consecutive fiscal quarters during the period from October 1, 2016 through September 30, 2017 from the sale of NARCAN® (the “Earn Out Milestone”), and then the Residual Royalty thereafter. (i) if the Earn Out Milestone is paid, then SWK shall receive 10% of all Royalties; provided, however, if no generic version of NARCAN® is commercialized prior to the sixth anniversary of the Closing, then SWK shall receive 5% of all Royalties after such date, and (ii) if the Earn Out Milestone is not paid, then SWK shall receive 7.86% of all Royalties; provided, however, that if no generic version of NARCAN® is commercialized prior to the sixth anniversary of the Closing, then SWK shall receive 3.93% of all Royalties after such date. 13,750,000 40,000 3,750,000 (i) the right to receive the statements produced by Adapt pursuant to Section 5.6 of the Adapt Agreement and (ii) the right, to the extent possible under the Purchase Agreement, to cure any breach of or default under any Product Agreement by the Company. Absent fraud by the Company, the Company’s indemnification obligations under the Purchase Agreement shall not exceed, individually or in the aggregate, an amount equal to the Purchase Price plus an annual rate of return of 12% (compounded monthly) as of any date of determination, with a total indemnification cap not to exceed 150% of the Purchase Price, less all Royalties received by SWK, without duplication, under the Purchase Agreement prior to and through resolution of the applicable claim. During the nine months ended April 30, 2017, the Company recognized proceeds of $ 13,710,000 On December 13, 2016, the Company and Adapt entered into Amendment No. 1 to the Adapt Agreement (the “Adapt Amendment”) which amends the terms of the Adapt Agreement relating to the grant of a commercial sublicense outside of the Unites States and diligence efforts for commercialization of the Company’s intranasal naloxone opioid overdose reversal treatment (the “Product”). Under the terms of the Adapt Amendment, Adapt is required to use commercially reasonable efforts to commercialize the Product in the U.S. In the event that Adapt wishes to grant a commercial sublicense to a third party in the European Union or the United Kingdom, the Company and Adapt have agreed to negotiate an additional amendment to the Adapt Agreement to include reduced financial terms with respect to the commercial sublicense in such territory. Under such terms, the Company would receive an escalating double-digit percentage of all net revenue received by Adapt from a commercial sublicensee in the European Union or the United Kingdom. Net revenue received by Adapt from a commercial sublicensee in European Union or the United Kingdom would be included in determining sales-based milestones due to the Company. On December 15, 2014, in connection with the Purchase Agreement, the Company and Adapt entered into the Adapt Agreement which provides Adapt with a global license to develop and commercialize the Product in exchange for the Company receiving potential development and sales milestone payments that could exceed $ 55

Potomac Amendment

Potomac Amendment	9 Months Ended
	Apr. 30, 2017
Potomac Amendment [Abstract]
Potomac Amendment	8. Potomac Amendment On April 12, 2017 (the “Potomac Effective Date”), the Company and Potomac Construction Limited (“Potomac”) entered into an amendment (the “Potomac Amendment”) to the following investment agreements with Potomac to provide for (in the case of Potomac Agreement No. 1 and Potomac Agreement No. 2 (each as defined below)), or modify (in the case of Potomac Agreement No. 3, Potomac Agreement No. 4 and Potomac Agreement No. 5 (each as defined below)), the Company’s right to buyback the Interest (as defined in each Potomac Amendment) in each Potomac Agreement (as defined below) from Potomac: (i) that certain Investment Agreement, dated as of April 16, 2013, as clarified by that certain letter agreement dated October 15, 2014 (“Potomac Agreement No. 1”); (ii) that certain Investment Agreement, dated as of May 30, 2013, as clarified by that certain letter agreement dated October 15, 2014 (“Potomac Agreement No. 2”); (iii) that certain Investment Agreement, dated as of September 9, 2014, as clarified by that certain letter agreement dated October 15, 2014 (“Potomac Agreement No. 3”); (iv) that certain Investment Agreement, dated as of October 31, 2014, as clarified by that certain letter agreement dated October 31, 2014 (“Potomac Agreement No. 4”); and (v) that certain Investment Agreement, dated as of December 8, 2015 (“Potomac Agreement No. 5”) ((i)–(v) collectively, the “Potomac Agreements” and, each, a “Potomac Agreement”). Pursuant to the Potomac Amendment, from the Potomac Effective Date until April 22, 2018, the five year anniversary of the date of the Investment (as defined in Potomac Agreement No. 1), the Company shall have the right to buyback all or any portion of the Interest (as defined in Potomac Agreement No. 1) from Potomac upon written notice to Potomac (the “Potomac Interest No. 1 Buyback Notice”), at the price of $600,000 per 6.0% of Interest (the “Potomac Interest No. 1 Buyback Amount”); provided provided further Pursuant to the Potomac Amendment, from the Potomac Effective Date until July 5, 2018, the five year anniversary of the latest date of the Investment (as defined in Potomac Agreement No. 2), the Company shall have the right to buyback all or any portion of the Interest (as defined in Potomac Agreement No. 2) from Potomac upon written notice to Potomac (the “Potomac Interest No. 2 Buyback Notice”), at the price of $150,000 per 1.5% of Interest (the “Potomac Interest No. 2 Buyback Amount”); provided provided further Pursuant to the Potomac Amendment, from the Potomac Effective Date until September 30, 2019, the five year anniversary of the date of the Investment (as defined in Potomac Agreement No. 3) (the “Potomac Interest No. 3 Buyback Expiration Date”), the Company shall have the right to buyback all or any portion of the Interest (as defined in Potomac Agreement No. 3) from Potomac upon written notice to Potomac (the “Potomac Interest No. 3 Buyback Notice”), at the price of $500,000 per 0.98% of Interest (the “Potomac Interest No. 3 Buyback Amount”); provided provided further Pursuant to the Potomac Amendment, from the Potomac Effective Date until November 28, 2019, the five year anniversary of the date of the Investment (as defined in Potomac Agreement No. 4) (the “Potomac Interest No. 4 Buyback Expiration Date”), the Company shall have the right to buyback all or any portion of the Interest (as defined in Potomac Agreement No. 4) from Potomac upon written notice to Potomac (the “Potomac Interest No. 4 Buyback Notice”), at the price of $500,000 per 0.98% of Interest (the “Potomac Interest No. 4 Buyback Amount”); provided provided further Pursuant to the Potomac Amendment, from the Potomac Effective Date until December 17, 2020, the five year anniversary of the date of the Investment (as defined in Potomac Agreement No. 5) (the “Potomac Interest No. 5 Buyback Expiration Date”), the Company shall have the right to buyback all or any portion of the Interest (as defined in Potomac Agreement No. 5) from Potomac upon written notice to Potomac (the “Potomac Interest No. 5 Buyback Notice”), at the price of $500,000 per 0.75% of Interest (the “Potomac Interest No. 5 Buyback Amount”); provided provided further Pursuant to the Potomac Amendment, if the Additional Investment (as defined in Potomac Agreement No. 5) is funded by Potomac, then, from the date of funding of such Additional Investment until the five year anniversary of such funding date (the “Potomac Additional Interest Buyback Expiration Date”), the Company shall have the right to buyback all or any portion of the Additional Interest (as defined in Potomac Agreement No. 5) upon written notice to Potomac (the “Potomac Additional Interest Buyback Notice”), at the price of $500,000 per 0.75% of Additional Interest (the “Potomac Additional Interest Buyback Amount”); provided provided further In consideration for Potomac entering into the Potomac Amendment, the Company has agreed to pay Potomac, within 15 business days of the Potomac Effective Date, $159,500. The Company recorded the $159,500 payment to Potomac as a non-recurring general and administrative expense. Furthermore, the Company shall grant Potomac the right to receive 2.5525% of the Net Profit (as defined in the Potomac Agreements) generated from DAVINCI (as defined in the Potomac Amendment). In the event that the Company is sold, Potomac shall receive 2.5525% of the net proceeds of such sale, after the deduction of all expenses and costs related to such sale. Additionally, from the Potomac Effective Date until the four year anniversary of the Potomac Effective Date (the “Potomac DAVINCI Interest Buyback Expiration Date”), the Company may buyback all or any portion of the DAVINCI Interest (as defined in the Potomac Amendment) upon written notice to Potomac (the “Potomac DAVINCI Interest Buyback Notice), at the price of $382,875 per 2.5525% of DAVINCI Interest (the “Potomac DAVINCI Interest Buyback Amount”); provided provided further that Furthermore, pursuant to the Potomac Amendment, the Company and Potomac agree that, upon the Company’s receipt after the Potomac Effective Date of at least $3 million from (i) SWK pursuant to the Purchase Agreement with SWK, or (ii) Adapt pursuant to the Adapt Agreement, fifty percent of all actual amounts received by the Company from SWK shall be used in determining the Net Profit.

Litigation

Litigation	9 Months Ended
	Apr. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Litigation	9. Litigation On September 15, 2016, the Company and Adapt Pharma, Inc. (“Adapt Inc.”) received notice from Teva Pharmaceuticals Industries Ltd. (“Teva Ltd.”) and Teva Pharmaceuticals USA, Inc., a wholly owned subsidiary of Teva Ltd. (“Teva USA” and, together with Teva Ltd., “Teva”), pursuant to 21 U.S.C. § 355(j)(2)(B)(ii) (the “September 2016 Notice Letter”), that Teva USA had filed ANDA No. 209522 (the “Teva ANDA”) with the FDA seeking regulatory approval to market a generic version of NARCAN® before the expiration of U.S. Patent No. 9,211,253 owned by the Company (the “’253 patent”). The ‘253 patent is listed with respect to NARCAN® in the FDA’s Approved Drug Products with Therapeutic Equivalents Evaluations publication (commonly referred to as the “Orange Book”) and expires on March 16, 2035. Teva’s September 2016 Notice Letter asserts that its generic product will not infringe the ‘253 patent and/or that the ‘253 patent is invalid or unenforceable. On October 21, 2016, Adapt Inc., Adapt Pharma Operations Limited (“Adapt”) and the Company (collectively, the “Plaintiffs”) filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey arising from Teva USA’s filing of the Teva ANDA with the FDA with respect to the ‘253 patent. The Plaintiffs seek, among other relief, an order that the effective date of FDA approval of the ‘253 ANDA be a date not earlier than the expiration of the ‘253 patent, as well as equitable relief enjoining Teva from making, using, offering to sell, selling, or importing the product that is the subject of the Teva ANDA until after the expiration of the ‘253 patent, and monetary relief as a result of any such infringement. On January 3, 2017, the Company and Adapt Inc. received notice from Teva, pursuant to 21 U.S.C. § 355(j)(2)(B)(ii) (the “January 2017 Notice Letter”), that Teva USA is seeking regulatory approval to market a generic version of NARCAN® before the expiration of U.S. Patent No. 9,468,747 (the “’747 patent”). The ‘747 patent is listed with respect to NARCAN® in the FDA’s Orange Book and expires on March 16, 2035. Teva’s January 2017 Notice Letter asserts that its generic product will not infringe the ‘747 patent or that the ‘747 patent is invalid or unenforceable. On February 8, 2017, the Plaintiffs filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey arising from Teva USA’s filing of the Teva ANDA with the FDA with respect to the ‘747 patent. The Plaintiffs seek, among other relief, an order that the effective date of FDA approval of the Teva ANDA be a date not earlier than the expiration of the ‘747 patent, as well as equitable relief enjoining Teva from making, using, offering to sell, selling, or importing the product that is the subject of the Teva ANDA until after the expiration of the ‘747 patent, and monetary relief as a result of any such infringement. On March 17, 2017, the Company and Adapt Inc. received notice from Teva, pursuant to 21 U.S.C. § 355(j)(2)(B)(ii) (the “March 2017 Notice Letter”), that Teva USA is seeking regulatory approval to market a generic version of NARCAN® before the expiration of U.S. Patent No. 9,561,177 (the “’177 patent”). The ‘177 patent is listed with respect to NARCAN® in the FDA’s Orange Book and expires on March 16, 2035. Teva’s March 2017 Notice Letter asserts that its generic product will not infringe the ‘177 patent and/or that the ‘177 patent is invalid or unenforceable. On April 26, 2017, the Plaintiffs filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey arising from Teva USA’s filing of the Teva ANDA with the FDA with respect to the ‘177 patent. The Plaintiffs seek, among other relief, an order that the effective date of FDA approval of the Teva ANDA be a date not earlier than the expiration of the ‘177 patent, as well as equitable relief enjoining Teva from making, using, offering to sell, selling, or importing the product that is the subject of the Teva ANDA until after the expiration of the ‘177 patent, and monetary relief as a result of any such infringement.

Subsequent Events

Subsequent Events	9 Months Ended
	Apr. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events Compensation Committee Addition On May 26, 2017, the Board voted to expand the Compensation Committee of the Board (the “Compensation Committee”) from two independent members to three independent members and appointed Gabrielle A. Silver, MD to the Compensation Committee. Following Dr. Silver’s appointment, the Compensation Committee is comprised of Ann MacDougall, JD (Chairperson), Dr. Silver, and Thomas T. Thomas. Sublease On May 29, 2017, the Company entered into a Sublease (the “Sublease”) with Standish Management, LLC to sublease office space located at 201 Santa Monica Boulevard, Santa Monica, CA 90401. Per the terms of the Sublease, the term will commence on September 1, 2017 and end on August 31, 2018 and the monthly rent will be $ 9,000 Welmers Investment Agreement Amendment On June 1, 2017 (the “Welmers Effective Date”), the Company and Ernst Welmers (“Welmers”) entered into an amendment (the “Welmers Amendment”) to that certain Investment Agreement, dated as of May 15, 2014, as clarified by that certain letter agreement dated October 15, 2014 (the “Welmers Agreement”), to provide for the Company’s right to buyback the Interest (as defined in the Welmers Agreement) from Welmers. Pursuant to the Welmers Amendment, from the Welmers Effective Date until May 27, 2019, the five year anniversary of the date of the Investment (as defined in the Welmers Agreement) (the “Welmers Interest Buyback Expiration Date”), the Company shall have the right to buyback all or any portion of the Interest from Welmers upon written notice to Welmers (the “Welmers Interest Buyback Notice”), at the price of $ 300,000 1.5 provided Welmers Interest Buyback Notice is provided within 3.25 years of the date of the Investment, the Company shall pay Welmers 1.8 times the Welmers Interest Buyback Amount within ten business days of providing the Welmers Interest Buyback Notice; provided further In consideration for Welmers entering into the Welmers Amendment, the Company has agreed to pay Welmers, within 15 business days of the Welmers Effective Date, $ 30,000 0.375 0.375 56,250 0.375 provided Welmers DAVINCI Interest Buyback Notice is provided within 2.5 years of the Welmers Effective Date, the Company shall pay Welmers two times the Welmers DAVINCI Interest Buyback Amount within ten business days of providing the Welmers DAVINCI Interest Buyback Notice; provided further that Furthermore, pursuant to the Welmers Amendment, the Company and Welmers agree that, upon the Company’s receipt after the Welmers Effective Date of at least $ 3 Amendment to LYL Holdings Amended and Restated Consulting Agreement On June 1, 2017 (the “LYL Effective Date”), the Company and LYL Holdings Inc. (“LYL”) entered into an amendment (the “LYL Amendment”) to that certain Amended and Restated Consulting Agreement, dated October 25, 2016 and effective as of July 17, 2013 (the “LYL Agreement”), to provide for the Company’s right to buyback the Interest (as defined in the LYL Agreement) from LYL. Pursuant to the LYL Amendment, from the LYL Effective Date until 4.5 years after July 17, 2013 (the “LYL Interest Buyback Expiration Date”), the Company shall have the right to buyback all or any portion of the Interest from LYL upon written notice to LYL (the “LYL Interest Buyback Notice”), at the price of $ 500,000 5.0 provided LYL Interest Buyback Notice is provided within 3.25 years of the LYL Effective Date, the Company shall pay LYL 1.8 times the LYL Interest Buyback Amount within ten business days of providing the LYL Interest Buyback Notice; provided further In consideration for LYL entering into the LYL Amendment, the Company and LYL agree that, upon the Company’s receipt after the LYL Effective Date of at least $ 3

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Apr. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the U.S. (“GAAP”), which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Opiant Pharmaceuticals UK Limited, a company incorporated on November 4, 2016 under the England and Wales Companies Act of 2006. Intercompany balances and transactions are eliminated upon consolidation.
Basic and Diluted Net Income (Loss) Per Share	Basic and Diluted Net Income (Loss) Per Share Earnings (loss) per share is calculated by dividing the net income (loss) available to common stockholders by the weighted average number of shares outstanding during the period. Diluted earnings per share reflect the potential dilution of securities that could share in earnings of an entity. Diluted income per share reflects the potential dilution that would occur if outstanding stock options and warrants were exercised utilizing the treasury stock method. In a loss year, dilutive common equivalent shares are excluded from the loss per share calculation as the effect would be anti-dilutive. For the Three Months Ended April 30, 2017 2016 Weighted Weighted Average Average Common Common Loss Shares Per Share Income Shares Per Share $ Outstanding $ $ Outstanding $ Basic: Income (loss) attributable to common stock (3,129,608) 2,014,141 (1.55) 416,128 1,916,554 0.22 Effective of Dilutive Securities: Stock options and warrants – – – – 818,206 – Diluted: Income (loss) attributable to common stock, including assumed conversions (3,129,608) 2,014,141 (1.55) 416,128 2,734,760 0.15 For the Nine Months Ended April 30, 2017 2016 Weighted Weighted Average Average Common Common Income Shares Per Share Loss Shares Per Share $ Outstanding $ $ Outstanding $ Basic: Income (loss) attributable to common stock 6,919,554 2,004,143 3.45 (6,723,849) 1,882,088 (3.57) Effective of Dilutive Securities: Stock options and warrants – 246,984 – – – – Diluted: Income (loss) attributable to common stock, including assumed conversions 6,919,554 2,251,127 3.07 (6,723,849) 1,882,088 (3.57)
Reclassification of Financial Statement Accounts	Reclassification of Financial Statement Accounts Certain amounts in the April 30, 2016 financial statements have been reclassified to conform to the presentation in the April 30, 2017 consolidated financial statements.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Apr. 30, 2017
Accounting Policies [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	A reconciliation of the components of basic and diluted net income (loss) per common share is presented in the tables below: For the Three Months Ended April 30, 2017 2016 Weighted Weighted Average Average Common Common Loss Shares Per Share Income Shares Per Share $ Outstanding $ $ Outstanding $ Basic: Income (loss) attributable to common stock (3,129,608) 2,014,141 (1.55) 416,128 1,916,554 0.22 Effective of Dilutive Securities: Stock options and warrants – – – – 818,206 – Diluted: Income (loss) attributable to common stock, including assumed conversions (3,129,608) 2,014,141 (1.55) 416,128 2,734,760 0.15 For the Nine Months Ended April 30, 2017 2016 Weighted Weighted Average Average Common Common Income Shares Per Share Loss Shares Per Share $ Outstanding $ $ Outstanding $ Basic: Income (loss) attributable to common stock 6,919,554 2,004,143 3.45 (6,723,849) 1,882,088 (3.57) Effective of Dilutive Securities: Stock options and warrants – 246,984 – – – – Diluted: Income (loss) attributable to common stock, including assumed conversions 6,919,554 2,251,127 3.07 (6,723,849) 1,882,088 (3.57)

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Apr. 30, 2017
Stockholders' Equity Note [Abstract]
Schedule of Assumptions Used in the Valuation	The assumptions used in the valuation for all of the options granted for the nine months ended April 30, 2017 and 2016 were as follows: 2017 2016 Market value of stock on measurement date $5.61 to 8.71 $ 7.00 Risk-free interest rate 0.88-2.55 % 2.05 % Dividend yield 0 % 0 % Volatility factor 97-348 % 373 % Term 2.53-10.00 years 10 years
Schedule of Options and Warrants Outstanding	Stock option activity for nine months ended April 30, 2017 is presented in the table below: Weighted- Weighted- Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Term (Years) Value Outstanding at July 31, 2016 4,635,000 $ 8.79 7.39 $ 2,731,250 Granted 320,000 $ 9.38 Expired (2,500) $ 10.00 Forfeited (1,180,000) $ 11.03 Outstanding at April 30, 2017 3,772,500 $ 8.13 7.12 $ 975,000 Exercisable at April 30, 2017 3,303,882 $ 7.75 7.21 $ 975,000 Warrant activity for the nine months ended April 30, 2017 is presented in the table below: Weighted- Weighted- Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Term (Years) Value Outstanding at July 31, 2016 1,215,385 $ 17.90 2.86 $ - Granted 45,000 $ 10.00 Expired (162,300) $ 47.23 Forfeited (325,000) $ 15.00 Outstanding at April 30, 2017 773,085 $ 12.51 3.27 $ - Exercisable at April 30, 2017 373,085 $ 9.84 6.06 $ -
Schedule of Nonvested Share Activity	Non-vested options Weighted Average Number of Grant Date Fair Options Value Non-vested at July 31, 2016 90,833 $ 7.27 Granted 320,000 $ 7.70 Vested (59,717) $ 6.93 Non-vested at April 30, 2017 351,116 $ 7.73

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Basic:
Income (loss) attributable to common stock	$ (3,129,608)	$ 416,128	$ 6,919,554	$ (6,723,849)
Diluted:
Income (loss) attributable to common stock, including assumed conversions	$ (3,129,608)	$ 416,128	$ 6,919,554	$ (6,723,849)
Weighted Average Common Shares Outstanding
Weighted Average Common Shares Outstanding, Basic	2,014,141	1,916,554	2,004,143	1,882,088
Weighted Average Common Shares Outstanding, Diluted	2,014,141	2,734,760	2,251,127	1,882,088
Effective of Dilutive Securities:
Stock options and warrants	0	818,206	246,984	0
Per Share Basic:
Earnings Per Share, Basic	$ (1.55)	$ 0.22	$ 3.45	$ (3.57)
Per Share Diluted:
Earnings Per Share, Diluted	$ (1.55)	$ 0.15	$ 3.07	$ (3.57)

Related Party Transactions (Det

Related Party Transactions (Details Textual) - USD ($)	1 Months Ended	9 Months Ended
	Mar. 31, 2017	Apr. 30, 2017	Apr. 30, 2016	Jul. 31, 2016
Related Party Transaction [Line Items]
Adjustments to Additional Paid in Capital, Other		$ 761,826	$ 0
Common Stock, Par or Stated Value Per Share		$ 0.001		$ 0.001
Board of Directors Chairman [Member]
Related Party Transaction [Line Items]
Related Party Transaction Penalty Rate	35.00%
Adjustments to Additional Paid in Capital, Other	$ 175,498
Stock Issued During Period, Shares, Share-based Compensation, Forfeited	680,000
Common Stock, Par or Stated Value Per Share	$ 0.001
Percentage of Options and Warrants	55.00%
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Related Party Transaction Penalty Rate	35.00%
Adjustments to Additional Paid in Capital, Other	$ 586,328
Stock Issued During Period, Shares, Share-based Compensation, Forfeited	825,000
Common Stock, Par or Stated Value Per Share	$ 0.001
Percentage of Options and Warrants	55.00%

Note Payable (Details Textual)

Note Payable (Details Textual) - USD ($)	1 Months Ended	9 Months Ended
	Jun. 21, 2016	Apr. 30, 2017	Apr. 30, 2016	Jul. 31, 2016
Debt Instrument [Line Items]
Accrued Professional Fees, Current	$ 165,000
Proceeds From Equity Or Debt Financing	$ 2,200,000
Common Stock, Shares, Outstanding		2,020,380		1,992,433
Repayments of Notes Payable		$ 165,000	$ 0
Securities Pledged as Collateral [Member]
Debt Instrument [Line Items]
Common Stock, Shares, Outstanding	22,916
Secured Promissory Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	6.00%

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Employee Stock Option [Member] - $ / shares	9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market value of stock on measurement date		$ 7
Risk-free interest rate		2.05%
Dividend yield	0.00%	0.00%
Volatility factor		373.00%
Term		10 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market value of stock on measurement date	$ 8.71
Risk-free interest rate	2.55%
Volatility factor	348.00%
Term	10 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market value of stock on measurement date	$ 5.61
Risk-free interest rate	0.88%
Volatility factor	97.00%
Term	2 years 6 months 11 days

Stockholders' Equity (Details 1

Stockholders' Equity (Details 1) - USD ($)	9 Months Ended	12 Months Ended
	Apr. 30, 2017	Jul. 31, 2016
Number of Shares
Granted	320,000
Stock Option [Member]
Number of Shares
Outstanding, Beginning Balance	4,635,000
Granted	320,000
Expired	(2,500)
Forfeited	(1,180,000)
Outstanding, Ending Balance	3,772,500	4,635,000
Exercisable	3,303,882
Weighted- average Exercise Price
Outstanding, Beginning Balance	$ 8.79
Granted	9.38
Expired	10
Forfeited	11.03
Outstanding, Ending Balance	8.13	$ 8.79
Exercisable	$ 7.75
Weighted- average Remaining Contractual Term (years)
Outstanding	7 years 1 month 13 days	7 years 4 months 20 days
Exercisable	7 years 2 months 16 days
Aggregate Intrinsic Value
Outstanding at July 31, 2016	$ 2,731,250
Outstanding at April 30, 2017	975,000	$ 2,731,250
Exercisable	$ 975,000

Stockholders' Equity (Details 2

Stockholders' Equity (Details 2)	9 Months Ended
	Apr. 30, 2017$ / sharesshares
Number of Options
Non-vested, Beginning Balance | shares	90,833
Granted | shares	320,000
Vested | shares	(59,717)
Non-vested, Ending Balance | shares	351,116
Weighted Average Grant Date Fair Value
Non-vested, Beginning Balance | $ / shares	$ 7.27
Granted | $ / shares	7.7
Vested | $ / shares	6.93
Non-vested, Ending Balance | $ / shares	$ 7.73

Stockholders' Equity (Details 3

Stockholders' Equity (Details 3) - Warrant [Member] - USD ($)	9 Months Ended	12 Months Ended
	Apr. 30, 2017	Jul. 31, 2016
Number of Shares
Outstanding, Beginning Balance	1,215,385
Granted	45,000
Expired	(162,300)
Forfeited	(325,000)
Outstanding, Ending Balance	773,085	1,215,385
Exercisable	373,085
Weighted- average Exercise Price
Outstanding, Beginning Balance	$ 17.90
Granted	10
Expired	47.23
Forfeited	15
Outstanding, Ending Balance	12.51	$ 17.90
Exercisable	$ 9.84
Weighted- average Remaining Contractual Term (years)
Outstanding	3 years 3 months 7 days	2 years 10 months 10 days
Exercisable	6 years 22 days
Aggregate Intrinsic Value
Outstanding		$ 0
Exercisable	$ 0

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)

Feb. 06, 2017

Feb. 03, 2017

Nov. 10, 2016

Nov. 04, 2016

Nov. 02, 2016

Oct. 06, 2016

Mar. 31, 2017

Mar. 16, 2017

Dec. 24, 2016

Nov. 19, 2015

Apr. 30, 2017

Apr. 30, 2017

Mar. 13, 2017

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock based compensation expense

$ 242,318

Stock Issued During Period, Value, Issued for Services

$ 190,427

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

59,717

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

320,000

Consultants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Issued During Period, Shares, Issued for Services

1,000

Stock Issued During Period, Value, Issued for Services

$ 7,520

Shares Issued, Price Per Share

$ 7.52

Consultants [Member] | November 2, 2016 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation, Total

$ 7,520

Advisor [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Issued During Period, Value, New Issues

$ 14,531

Stock Issued During Period, Shares, New Issues

1,875

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 10

Warrants and Rights Outstanding

$ 229,360

229,360

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

45,000

Shares Issued, Price Per Share

$ 7.75

Advisor [Member] | March 16, 2017 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation, Total

14,531

Chief Scientific Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

200,000

Board of Directors Chairman [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Forfeited

680,000

Chief Executive Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Forfeited

825,000

Warrant [Member] | Advisor [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

3 years

Share Price

$ 8

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price

$ 10

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

111.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.63%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

3 years

Treasury Bond, Term

3 years

Warrant [Member] | Board of Directors Chairman [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Forfeited

285,000

Warrant [Member] | Chief Executive Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Forfeited

40,000

Letter Of Intent [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Issued During Period, Value, New Issues

$ 85,102

$ 83,274

$ 120,347

Stock Issued During Period, Shares, New Issues

14,327

10,745

14,327

Shares Issued, Price Per Share

$ 5.94

$ 7.75

Letter Of Intent [Member] | November 10, 2016 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation, Total

85,102

Letter Of Intent [Member] | March 16, 2017 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation, Total

83,274

Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock based compensation expense

213,282

Fair value of option granted

$ 425,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

320,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 9.38

Stock Option [Member] | Thomas T. Thomas [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock based compensation expense

$ 134,188

Fair value of option granted

220,116

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

vests as follows: (i) 11,667 shares vest upon the uplisting of the Company to the NASDAQ Stock Market; (ii) 11,667 shares vest upon the cumulative funding of the Company of or in excess of $5,000,000 by institutional investors starting from November 4, 2016; and 11,666 shares vest upon the first submission of a New Drug Application to the U.S. Food and Drug Administration for one of Companys products by Company itself or a Company licensee.

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

35,000

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

5 years

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 10

Stock Option [Member] | Employee [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock based compensation expense

75,363

Fair value of option granted

219,450

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

35,000

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 10

Stock Option [Member] | Two Employees [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

50,000

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 10

Stock Option [Member] | Chief Scientific Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation, Total

223,925

Fair value of option granted

$ 1,600,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

200,000

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 9

Additional Share Based Compensation

1,376,075

Stock Option [Member] | Board of Directors Chairman [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Forfeited

395,000

Stock Option [Member] | Chief Executive Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Forfeited

785,000

Stock Option [Member] | Share-based Compensation Award, Tranche One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

1,388

Stock Option [Member] | Share-based Compensation Award, Tranche One [Member] | Employee [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

972

Stock Option [Member] | Share-based Compensation Award, Tranche One [Member] | Chief Scientific Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

100,000

Stock Option [Member] | Share-based Compensation Award, Tranche Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

1,390

973

Stock Option [Member] | Share-based Compensation Award, Tranche Two [Member] | Chief Scientific Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

5,555

Stock Option [Member] | Share-based Compensation Award, Tranche Three [Member] | Chief Scientific Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

5,556

Non Vested Stock Options [Member] | Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Unrecognized stock-based compensation cost

$ 2,001,413

$ 2,001,413

Commitments (Details Textual)

Commitments (Details Textual)	Mar. 13, 2017USD ($)$ / sharesshares	Feb. 03, 2017USD ($)shares	Nov. 10, 2016USD ($)$ / sharesshares	Apr. 20, 2017GBP (£)	Mar. 16, 2017USD ($)$ / sharesshares	Oct. 31, 2016USD ($)	Nov. 19, 2015USD ($)shares	Apr. 30, 2017USD ($)	Apr. 30, 2016USD ($)	Apr. 30, 2017USD ($)shares	Apr. 30, 2017GBP (£)shares	Apr. 30, 2016USD ($)	Jul. 31, 2016USD ($)shares	Jul. 31, 2015USD ($)	Mar. 31, 2017USD ($)	Nov. 02, 2016$ / shares
Selling Expense								$ 84,375	$ 93,000	$ 1,322,974		$ 302,251
Percentage of Royalty Net Sales						3.00%
Percentage of Royalty Sublicensed						4.00%
Payments For Minimum Annual Royalty								10,000		10,000
Fixed Milestone Payments								$ 715,672		$ 715,672
Consultant's Fee, Description										the consultants fee will be equal to 5% of gross funding received by the Company up to $20,000,000 plus 3.5% of any proceeds received in excess of $20,000,000	the consultants fee will be equal to 5% of gross funding received by the Company up to $20,000,000 plus 3.5% of any proceeds received in excess of $20,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares										320,000	320,000
Consultants [Member]
Selling Expense										$ 687,500		0
Shares Issued, Price Per Share | $ / shares																$ 7.52
Chief Scientific Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares		200,000
Chief Scientific Officer [Member] | Deferred Bonus [Member]
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount		$ 40,000
Advisor [Member]
Stock Issued During Period, Shares, New Issues | shares					1,875
Stock Issued During Period, Value, New Issues					$ 14,531
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount	$ 107,805														$ 17,000
Deferred Compensation Arrangement, Cash Awards Granted As a Percentage of Net Sales	1.25%
Deferred Compensation Arrangement, Cash Awards Granted As a Percentage of Net Proceeds from Divestiture	1.25%
Deferred Compensation Arrangement, Percentage of Shares Authorized for Repurchase	1.25%
Shares Issued, Price Per Share | $ / shares					$ 7.75
Deferred Compensation Arrangement Amount Authorized For Repurchase	$ 187,500
Advisor [Member] | March 16, 2017 [Member]
Share-based Compensation										14,531
Advisor [Member] | Common Stock [Member]
Deferred Compensation Arrangement with Individual, Shares Issued | shares	1,875
Advisor [Member] | Warrant [Member]
Deferred Compensation Arrangement with Individual, Shares Issued | shares	45,000
Deferred Compensation Arrangement with Individual, Exercise Price | $ / shares	$ 10
Letter Of Intent [Member]
Additional Stock Issue During Period Upon Milestones | shares							92,634
Stock Issued During Period, Shares, New Issues | shares			14,327		10,745		14,327
Stock Issued During Period, Value, New Issues			$ 85,102		$ 83,274		$ 120,347
Shares, Issued | shares													3,582
Shares Issued, Price Per Share | $ / shares			$ 5.94		$ 7.75
Letter Of Intent [Member] | March 16, 2017 [Member]
Share-based Compensation										$ 83,274
Adapt Pharma Operations Limited [Member]
Payments for Other Fees													$ 225,000	$ 75,000
Additional Consultant Fee Payable, Percentage								3.75%		3.75%
Operating Leases, Rent Expense										$ 3,000,000
Selling Expense										209,251		$ 635,474
Euston Tower Serviced Offices Ltd [Member]
Operating Leases, Rent Expense | £											£ 1,932
Premier Office Centers, LLC [Member]
Operating Leases, Monthly Rent Expense						$ 5,056				$ 5,157
Description of Lessee Leasing Arrangements, Operating Leases										The New Lease became effective March 1, 2017, the date after which the term of the current lease with Premier expires. Pursuant to the terms of the New Lease, the Company will pay $5,157 per month to Premier. The New Lease has an initial term of 12 months and shall automatically renew for successive 12 month periods unless terminated by the Company at least 60 days prior to the termination date. Premier may terminate the New Lease for any reason upon 30 days’ notice to the Company.	The New Lease became effective March 1, 2017, the date after which the term of the current lease with Premier expires. Pursuant to the terms of the New Lease, the Company will pay $5,157 per month to Premier. The New Lease has an initial term of 12 months and shall automatically renew for successive 12 month periods unless terminated by the Company at least 60 days prior to the termination date. Premier may terminate the New Lease for any reason upon 30 days’ notice to the Company.
Regus Management Group, LLC [Member]
Operating Leases, Monthly Rent Expense				£ 7,521						$ 299
Lease Expiration Date				May 31, 2018						Jul. 31, 2017	Jul. 31, 2017
Operating Leases, Rent Expense | £				£ 2,473
Security Deposit | £				£ 15,042

Sale of Royalties (Details Text

Sale of Royalties (Details Textual) - USD ($)	Dec. 13, 2016	Apr. 30, 2017	Dec. 15, 2014
License Agreement Amendment Description	(i) $20,625,000 and then the Residual Royalty thereafter or (ii) $26,250,000, if Adapt has received in excess of $25,000,000 of cumulative Net Sales for any two consecutive fiscal quarters during the period from October 1, 2016 through September 30, 2017 from the sale of NARCAN (the Earn Out Milestone), and then the Residual Royalty thereafter.
Residual Royalty Defined In Purchase Agreement	(i) if the Earn Out Milestone is paid, then SWK shall receive 10% of all Royalties; provided, however, if no generic version of NARCAN is commercialized prior to the sixth anniversary of the Closing, then SWK shall receive 5% of all Royalties after such date, and (ii) if the Earn Out Milestone is not paid, then SWK shall receive 7.86% of all Royalties; provided, however, that if no generic version of NARCAN is commercialized prior to the sixth anniversary of the Closing, then SWK shall receive 3.93% of all Royalties after such date.
Purchase Agreement Grants Description	(i) the right to receive the statements produced by Adapt pursuant to Section 5.6 of the Adapt Agreement and (ii) the right, to the extent possible under the Purchase Agreement, to cure any breach of or default under any Product Agreement by the Company.
Upfront Purchase Price Received Under Purchase Agreement	$ 13,750,000
Milestone Payment Receivable Under Purchase Agreement	$ 3,750,000
Indemnification Obligations Under Purchase Agreement Description	Absent fraud by the Company, the Companys indemnification obligations under the Purchase Agreement shall not exceed, individually or in the aggregate, an amount equal to the Purchase Price plus an annual rate of return of 12% (compounded monthly) as of any date of determination, with a total indemnification cap not to exceed 150% of the Purchase Price, less all Royalties received by SWK, without duplication, under the Purchase Agreement prior to and through resolution of the applicable claim.
Finite-Lived License Agreements, Gross			$ 55,000,000
Legal Fees	$ 40,000
Deferred Revenue, Revenue Recognized		$ 13,710,000

Potomac Amendment (Details Text

Potomac Amendment (Details Textual)	Apr. 12, 2017USD ($)shares
Potomac Construction Limited [Member]
Potomac Amendment [Line Items]
Other Financing Securities Buyback Terms	the Potomac DAVINCI Interest Buyback Notice is provided within 2.5 years of the Potomac Effective Date, the Company shall pay Potomac two times the Potomac DAVINCI Interest Buyback Amount within ten business days of providing the Potomac DAVINCI Interest Buyback Notice; provided, further, that, in the event the Potomac DAVINCI Interest Buyback Notice is provided after 2.5 years of the Potomac Effective Date and on or prior to the Potomac DAVINCI Interest Buyback Expiration Date, the Company shall pay Potomac 3.5 times the Potomac DAVINCI Interest Buyback Amount within ten business days of providing the Potomac DAVINCI Interest Buyback Notice.
Deferred Compensation Arrangement, Cash Awards Granted As a Percentage of Net Proceeds from Divestiture	2.5525%
Deferred Compensation Arrangement, Shares Authorized for Repurchase | shares	382,875
Deferred Compensation Arrangement, Percentage of Shares Authorized for Repurchase	2.5525%
Deferred Compensation Arrangement Cash Awards Granted As Percentage Of Net Profit	2.5525%
Deferred Compensation Arrangement with Individual, Recorded Liability	$ 159,500
Potomac Construction Limited [Member] | General and Administrative Expense [Member]
Potomac Amendment [Line Items]
Other Nonrecurring Expense	159,500
Potomac Construction Limited [Member] | Potomac Amendment One [Member]
Potomac Amendment [Line Items]
Proceeds from (Payments for) Other Financing Activities	$ 600,000
Percentage Interest In Asset	6.00%
Other Financing Securities Buyback Terms	the Potomac Interest No. 1 Buyback Notice is provided within 3.25 years of the date of the Investment, the Company shall pay Potomac 1.8 times the Potomac Interest No. 1 Buyback Amount within ten business days of providing the Potomac Interest No. 1 Buyback Notice; provided, further, that in the event the Potomac Interest No. 1 Buyback Notice is provided after 3.25 years of the date of the Investment and no later than 4.25 years from the date of the Investment, the Company shall pay Potomac 3.15 times the Potomac Interest No. 1 Buyback Amount within ten business days of providing the Potomac Interest No. 1 Buyback Notice.
Potomac Construction Limited [Member] | Potomac Amendment Two [Member]
Potomac Amendment [Line Items]
Proceeds from (Payments for) Other Financing Activities	$ 150,000
Percentage Interest In Asset	1.50%
Other Financing Securities Buyback Terms	the Potomac Interest No. 2 Buyback Notice is provided within 3.25 years of the date of the Investment, the Company shall pay Potomac 1.8 times the Potomac Interest No. 2 Buyback Amount within ten business days of providing the Potomac Interest No. 2 Buyback Notice; provided, further, that in the event the Potomac Interest No. 2 Buyback Notice is provided after 3.25 years of the date of the Investment and no later than 4.25 years from the date of the Investment, the Company shall pay Potomac 3.15 times the Potomac Interest No. 2 Buyback Amount within ten business days of providing the Potomac Interest No. 2 Buyback Notice.
Potomac Construction Limited [Member] | Potomac Amendment Three [Member]
Potomac Amendment [Line Items]
Proceeds from (Payments for) Other Financing Activities	$ 500,000
Percentage Interest In Asset	0.98%
Other Financing Securities Buyback Terms	the Potomac Interest No. 3 Buyback Notice is provided within 3.25 years of the date of the Investment, the Company shall pay Potomac 1.8 times the Potomac Interest No. 3 Buyback Amount within ten business days of providing the Potomac Interest No. 3 Buyback Notice; provided, further, that in the event the Potomac Interest No. 3 Buyback Notice is provided after 3.25 years of the date of the Investment and on or prior to the Potomac Interest No. 3 Buyback Expiration Date, the Company shall pay Potomac 3.15 times the Potomac Interest No. 3 Buyback Amount within ten business days of providing the Potomac Interest No. 3 Buyback Notice.
Potomac Construction Limited [Member] | Potomac Amendment Four [Member]
Potomac Amendment [Line Items]
Proceeds from (Payments for) Other Financing Activities	$ 500,000
Percentage Interest In Asset	0.98%
Other Financing Securities Buyback Terms	the Potomac Interest No. 4 Buyback Notice is provided within 3.25 years of the date of the Investment, the Company shall pay Potomac 1.8 times the Potomac Interest No. 4 Buyback Amount within ten business days of providing the Potomac Interest No. 4 Buyback Notice; provided, further, that in the event the Potomac Interest No. 4 Buyback Notice is provided after 3.25 years of the date of the Investment and on or prior to the Potomac Interest No. 4 Buyback Expiration Date, the Company shall pay Potomac 3.15 times the Potomac Interest No. 4 Buyback Amount within ten business days of providing the Potomac Interest No. 4 Buyback Notice.
Potomac Construction Limited [Member] | Potomac Amendment Five [Member]
Potomac Amendment [Line Items]
Proceeds from (Payments for) Other Financing Activities	$ 500,000
Percentage Interest In Asset	0.75%
Other Financing Securities Buyback Terms	the Potomac Interest No. 5 Buyback Notice is provided within 3.25 years of the date of the Investment, the Company shall pay Potomac 1.8 times the Potomac Interest No. 5 Buyback Amount within ten business days of providing the Potomac Interest No. 5 Buyback Notice; provided, further, that in the event the Potomac Interest No. 5 Buyback Notice is provided after 3.25 years of the date of the Investment and on or prior to the Potomac Interest No. 5 Buyback Expiration Date, the Company shall pay Potomac 3.15 times the Potomac Interest No. 5 Buyback Amount within ten business days of providing the Potomac Interest No. 5 Buyback Notice.
Potomac Construction Limited [Member] | Potomac Amendment Five Additional [Member]
Potomac Amendment [Line Items]
Proceeds from (Payments for) Other Financing Activities	$ 500,000
Percentage Interest In Asset	0.75%
Other Financing Securities Buyback Terms	Additional Interest Buyback Notice is provided within 3.25 years of the date of the Additional Investment, the Company shall pay Potomac 1.8 times the Potomac Additional Interest Buyback Amount within ten business days of providing the Potomac Additional Interest Buyback Notice; provided, further, that in the event the Potomac Additional Interest Buyback Notice is provided after 3.25 years of the date of the Additional Investment and on or prior to the Potomac Additional Interest Buyback Expiration Date, the Company shall pay Potomac 3.15 times the Potomac Additional Interest Buyback Amount within ten business days of providing the Potomac Additional Interest Buyback Notice. However, Potomac opted, at its sole discretion, not to make the $1,000,000 Additional Investment, and the deadline for Potomac to make the Additional Investment has passed.
SWK Funding LLC [Member]
Potomac Amendment [Line Items]
Proceeds from (Payments for) Other Financing Activities	$ 3,000,000
Proceeds for Percentage of Used in Determining Net Profit	50.00%

Subsequent Events (Details Text

Subsequent Events (Details Textual) - USD ($)	Apr. 12, 2017	Jun. 01, 2017	May 29, 2017
SWK Funding LLC [Member]
Subsequent Event [Line Items]
Proceeds from (Payments for) Other Financing Activities	$ 3,000,000
Subsequent Event [Member] | Ernst Welmers [Member]
Subsequent Event [Line Items]
Deferred Compensation Arrangement, Cash Awards Granted As a Percentage of Net Proceeds from Divestiture		0.375%
Deferred Compensation Arrangement, Percentage of Shares Authorized for Repurchase		1.50%
Deferred Compensation Arrangement Amount Authorized For Repurchase		$ 300,000
Other Financing Securities Buyback Terms		Welmers Interest Buyback Notice is provided within 3.25 years of the date of the Investment, the Company shall pay Welmers 1.8 times the Welmers Interest Buyback Amount within ten business days of providing the Welmers Interest Buyback Notice;provided,further, that in the event the Welmers Interest Buyback Notice is provided after 3.25 years of the date of the Investment and on or prior to the Welmers Interest Buyback Expiration Date, the Company shall pay Welmers 3.15 times the Welmers Interest Buyback Amount within ten business days of providing the Welmers Interest Buyback Notice.
Deferred Compensation Arrangement with Individual, Recorded Liability		$ 30,000
Deferred Compensation Arrangement Cash Awards Granted As Percentage Of Net Profit		0.375%
Subsequent Event [Member] | Welmers DAVINCI Investment Agreement Amendment [Member] | Ernst Welmers [Member]
Subsequent Event [Line Items]
Deferred Compensation Arrangement, Percentage of Shares Authorized for Repurchase		0.375%
Deferred Compensation Arrangement Amount Authorized For Repurchase		$ 56,250
Other Financing Securities Buyback Terms		Welmers DAVINCI Interest Buyback Notice is provided within 2.5 years of the Welmers Effective Date, the Company shall pay Welmers two times the Welmers DAVINCI Interest Buyback Amount within ten business days of providing the Welmers DAVINCI Interest Buyback Notice;provided,further,that, in the event the Welmers DAVINCI Interest Buyback Notice is provided after 2.5 years of the Welmers Effective Date and on or prior to the Welmers DAVINCI Interest Buyback Expiration Date, the Company shall pay Welmers 3.5 times the Welmers DAVINCI Interest Buyback Amount within ten business days of providing the Welmers DAVINCI Interest Buyback Notice.
Subsequent Event [Member] | Standish Management, LLC [Member]
Subsequent Event [Line Items]
Operating Leases, Rent Expense, Sublease Rentals			$ 9,000
Subsequent Event [Member] | SWK Funding LLC [Member]
Subsequent Event [Line Items]
Proceeds from (Payments for) Other Financing Activities		$ 3,000,000
Subsequent Event [Member] | LYL Holdings Inc [Member]
Subsequent Event [Line Items]
Proceeds from (Payments for) Other Financing Activities		$ 3,000,000
Deferred Compensation Arrangement, Percentage of Shares Authorized for Repurchase		5.00%
Deferred Compensation Arrangement Amount Authorized For Repurchase		$ 500,000
Other Financing Securities Buyback Terms		LYL Interest Buyback Notice is provided within 3.25 years of the LYL Effective Date, the Company shall pay LYL 1.8 times the LYL Interest Buyback Amount within ten business days of providing the LYL Interest Buyback Notice;provided,further, that in the event the LYL Interest Buyback Notice is provided after 3.25 years after the Effective Date and on or prior to the LYL Interest Buyback Expiration Date, the Company shall pay LYL 3.15 times the LYL Interest Buyback Amount within ten business days of providing the LYL Interest Buyback Notice.